

# **Covid Conflicts of Interest**

## **Follow the Money**

**Monday, 18 July 2022**

**Fahrie Hassan**



General Assembly #49  
**World Council  
For Health**

# The Global Public Private Partnership

## Policy Makers

This is the part of the GPPP where policy originates.

B.I.S.

Bank for International Settlements (B.I.S.)

They ultimately control the money supply and thus global markets, trade and national economies.

Central Banks

Central Banks (Coordinated by the B.I.S.)

They are "going direct" and directly funding government spending. Monetary policy has effectively become fiscal policy.

W.E.F.

C.F.R.

Club of Rome

Chatham House

Rockefellers

Think Tanks & Global Representative Groups

These formulate the policies to achieve GPPP objectives. Resource allocation determined by the B.I.S. and Central Banks but they work in "partnership" with the think tanks and the representative bodies to convert that into global political policy.

## Policy Distributers

United Nations

IMF

I.P.C.C

World Bank

W.H.O

Philanthropists

Global Corp's

N.G.O

These organisations and bodies take policy directives from the policy makers and distribute them to the policy enforcers.

## Policy Enforcers

**National Governments**  
Civil Service, NHS, RRU, IPSO, Dfcom, Police, Military, Courts, Local Governments, Statutory Agencies etc.

**Selected Scientific Authorities**  
SAGE, NERVTAG, ICL, MHRA, JCVI etc.

The Policy Enforcers exploit or work with the Selected Scientific Authorities to justify the policies they are required to enforce.

## Policy Propagandists

**Propagandists and Hybrid Warfare Specialists**  
M.S.M, Fact Checkers (PolitiFact, Full Fact etc.), Social Media Platforms, Hybrid Warriors (77th Brigade, Huteighteen etc.), Anti-Hate Campaigners (CCE, CCDH etc)

The propagandists and hybrid warfare specialists are tasked with convincing the public to accept and hopefully believe in the policies. They use psychological manipulation, disinformation, misinformation, censorship and propaganda.

## Policy Subjects

**The Public**

We are the subjects of the policy which cascades down through the GPP system. We largely pay for the system through taxation and public borrowing. The system is designed to exploit us but we are an increasingly unnecessary component as the GPPP look to seize the global commons.

# The Rulers of the World

The Rothschild Investment Corp. and the Edmond De Rothschild Holdings

**Big Media**

News Corp,  
Disney,  
Comcast  
Time Warner  
The New York Times

are the two largest stakeholders in Vanguard and Blackrock



**Vanguard**  
\$7.50 trillion

\$2,080 trillion



**Rothschild & Co**



**EDMOND DE ROTHSCHILD**

**BlackRock**  
\$9.2 trillion

Orsini family (Italy), Bush family (USA), the British Royal family, the Morgans, Vanderbilts du Pont family and Rockefellers  
Are all owners of Vanguard and BlackRock

Pfizer  
Johnson & Johnson  
AstraZeneca  
Merck  
GlaxoSmithKline

**Big Pharma**

BlackRock and Vanguard form a secret monopoly, combined ownership encompasses nearly 90% of all S&P 500 firms.

# Control of Big Pharma

---

---

**BlackRock**®

**Vanguard**®


**STATE STREET**®

## Top Institutional Share Holders

Total: \$9.2 trillion

<https://www.holdingschannel.com/all/stocks-held-by-blackrock-inc/>

Holder	Shares	Value (\$)
Vanguard Group, Inc.	12,124,607	10,608,667,386
Blackrock Inc.	9,903,465	8,665,234,771
State Street Corporation	6,362,736	5,567,203,117
Bank of America Corporation	5,839,903	5,109,739,927
FMR, LLC	3,892,865	3,406,140,089
JP Morgan Chase & Company	2,542,122	2,224,280,486
CARLYLE GROUP INC	7,764,706	360,904
TWITTER INC		3,626,098
<b>JOHNSON &amp; JOHNSON</b>	<b>191,385,110</b>	<b>31,528,781</b>
<b>PFIZER INC</b>	<b>407,048,272</b>	<b>15,940,011</b>
<b>MRNA / Moderna Inc</b>	<b>19,390,725</b>	<b>4,556,434,000</b>
<b>ASTRAZENECA PLC</b>	<b>8,174,7</b>	<b>489,668</b>
<b>BIONTECH SE</b>	<b>1,481,390</b>	<b>331,654</b>
<b>NOVAVAX INC</b>		<b>970,594</b>
<b>SANOFI</b>	<b>14,538,448</b>	<b>765,593</b>
<b>MERCK &amp; CO INC</b>	<b>187,155,493</b>	<b>14,555,084</b>
<b>ELI LILLY &amp; CO</b>	<b>60,927,657</b>	<b>13,984,117</b>
<b>GILEAD SCIENCES INC</b>	<b>123,804,538</b>	<b>8,525,183</b>
<b>BRISTOL MYERS SQUIBB CO</b>	<b>175,100,707</b>	<b>11,700,230</b>
<b>BIOGEN INC</b>	<b>13,206,591</b>	<b>4,573,047</b>
<b>ILLUMINA INC</b>		<b>5,314,852</b>






**Vanguard**<sup>®</sup>

## Vanguard High Dividend Yield Index Fund

[Stock holdings](#) | [Bond holdings](#) | [Short-term reserve holdings](#)

as of: 08/31/2021

Stock Holdings		
Total: \$7.50 trillion		
Holding 	Shares 	Market Value 
Johnson & Johnson	9,724,171	\$1,683,545,725
Pfizer Inc.	20,595,438	\$948,831,829
Merck & Co. Inc.	9,346,496	\$713,044,180
Gilead Sciences Inc.	4,634,044	\$337,265,722
Eli Lilly & Co.	3,127,195	\$807,723,197
Bristol-Myers Squibb Co.	8,241,776	\$551,045,143
Comcast Corp. Class A	16,825,781	\$1,020,988,391
Carlyle Group Inc.	595,138	\$29,387,914
AT&T Inc.	26,355,223	\$722,660,215
Citigroup Inc.	7,625,547	\$548,353,085
Bank of America Corp.	27,833,088	\$1,162,031,424
Carlyle Group Inc.	595,138	\$29,387,914
BlackRock Inc.	427,258	\$403,028,199

## State Street Corp - Latest 13F Holdings, Performance, AUM

Market Value - \$2.81 trillion

File Date	Form	Security	Prev Shares	Current Shares			
2021-09-10	13G	ALT / Altimmune Inc	3,991,141				
2021-06-30	13F	PFE / Pfizer Inc.	278,568,311	1.34	10,908,735	9.53	
2021-06-30	13F	JNJ / Johnson & Johnson	142,047,884	1.27	23,400,968	1.51	
2021-06-30	13F	AZN / AstraZeneca Plc	239,870	-17.45	14,368	-0.55	
2021-06-30	13F	MRNA / Moderna Inc	7,325,576	21.91	1,721,364	118.76	
2021-06-30	13F	NVAX / Novavax, Inc.	1,693,390	17.44	359,524	37.52	
2021-06-30	13F	INO / Inovio Pharmaceuticals	8,907,158	7.89	82,569	7.78	
2021-06-30	13F	MRK / Merck & Co., Inc.	114,073,945	1.23	8,943,537	2.11	
2021-06-30	13F	GSK / GlaxoSmithKline plc	9,163,297	-2.25	369,759	8.62	
2021-06-30	13F	LLY / Eli Lilly And Co	32,927,576	1.30	7,557,537	24.45	
2021-02-16	13G/A	MYGN / Myriad Genetics, Inc.	3,715,530				
2021-06-30	13F	NVS / Novartis AG	2,039,489	1.63	186,083	8.48	
2021-06-30	13F	BIO / Bio-Rad Laboratories, Inc.	974,441	0.28	627,823	13.12	
2021-06-30	13F	PKI / PerkinElmer, Inc.	4,435,573	1.47	684,897	22.13	
2021-06-30	13F	BMJ / Bristol-Myers Squibb Co	92,145,348	1.32	6,157,152	6.42	
2021-06-30	13F	ILMN / Illumina, Inc.	5,869,364	1.77	2,777,442	25.39	
2021-06-30	13F	ABT / Abbott Laboratories	71,745,046	1.73	8,317,403	-1.59	
2021-06-30	13F	NYT / New York Times Co	3,808,484	8.59	165,859	-6.58	
2021-06-30	13F	BRK.A / Berkshire Hathaway, Inc.	192	-9.43	80,371	-1.71	
2021-06-30	13F	BRK.B / Berkshire Hathaway,	78,524,981	0.03	21,823,663	8.82	
2021-06-30	13F	BNDX / Vanguard Total International Bond Index Fund	308,072	38.75	17,591	38.71	

STATE STREET®

Covid  
Vaccine  
CandidateCovid  
Auxiliary  
IndustryCovid  
Investments





• **trial**

## Trial Sponsors



## Trial Partners



## Trial Funders

FAST — GRANTS



## Research Network



uOttawa



UFOP

Universidade Federal  
de Ouro Preto



## Trial Investigators



**Dr Edward Mills**  
Co-Principal Investigator  
Health Research Methods, Evidence, and  
Impact, McMaster University, Canada



**Dr Gilmar Reis**  
Co-Principal Investigator  
Heart Institute, School of Medicine  
University of Sao Paulo



**Dr Craig R. Rayner**  
Senior Investigator  
Associate Professor,  
Monash University



**Dr David Boulware**  
Senior Investigator  
Prof Medicine, Univ of Minnesota



**Dr Gordan Guyatt**  
Senior Investigator  
Health Research Methods, Evidence, and  
Impact, McMaster University, Canada



**Dr Francois Venter**  
Senior Investigator  
Director of Ezintsha,  
Univ of Witwatersrand



**Dr. Mark Dybul**  
Senior Investigator  
Professor Dept of Medicine  
Executive Officer, Enochian Biosciences



**Dr Zulfiqar A. Bhutta**  
Senior Investigator  
Professor Nutritional Sciences  
Univ of Toronto



**Dr Sabin Nsanzimana**  
Senior Investigator  
Director General of The University  
Teaching Hospital of Butare, Rwanda



**Dr Jeffrey S. Glenn**  
Senior Investigator  
Professor of Microbiology and  
Immunology, Stanford University

# together • COVID-19 trial : Dr Edward Mills

clinical trials

Jack Dorsey 	Chan & Mark Zuckerberg 	CRANKSTART Michael Moritz  Founder Patrick Collison
Elon Musk 	FAST — GRANTS 	 Eric Schmidt SCHMIDT FUTURES
Reid Hoffman 	Mackenzie Bezos	 

**Principal Investigator**



**Dr. Edward Mills**  
Health Research Methods,  
Evidence, and Impact

PUC Minas

McMaster University  
Associate Professor

NORDIC CAPITAL astorg.  
**Cytel**  
Senior principal scientist

Daiichi-Sankyo

SANOFI

PLATFORM LIFE SCIENCES

Pfizer

NOVAQUEST  
CAPITAL MANAGEMENT

REGENERON  
SCIENCE TO MEDICINE<sup>®</sup>

Medicines Development  
for Global Health

AstraZeneca

Australian Government

ALIMA

**Funder**

unicef

FIND  
Because diagnosis matters

UNIVERSITY OF LIVERPOOL

ITPC  
INTERNATIONAL TREATMENT PROMPTNESS COALITION

World Health Organization

psi

CLINTON HEALTH ACCESS INITIATIVE

Unitaid  
Innovation in Global Health

PATH

THE AURUM INSTITUTE

The Global Fund

wellcome

medicines patent pool

University of the Witwatersrand  
WITS RHI

MEDECINS SANS FRONTIERES

BILL & MELINDA GATES foundation  
Clinical Trials Advisor

**Funder**

FTX  
**Funder**

MMS  
The difference is in the data.<sup>™</sup>

**MMS Holdings**

**Funder**

BlackRock

Vanguard

STATE STREET

Vanguard

BlackRock

Biogen

RAINWATER  
Charitable Foundation

Lilly

abbvie

Tau Consortium

CUREPSP  
UNLOCKING THE SECRETS OF BRAIN DISEASE<sup>™</sup>

janssen  
PHARMACEUTICAL COMPANIES  
of Johnson & Johnson



# together • COVID-19 : Dr Andrew Hill – Conflicts of Interest

## RAINWATER CHARITABLE FOUNDATION

• FORT WORTH, TX [How do I update this listing?](#)

[Download 13F Summary](#) [Create Email Alert](#)

Rainwater Charitable Foundation is based out of Fort Worth. Their last reported 13F filing for Q1 2022 included \$150,899,000 in managed 13F securities and a top 10 holdings concentration of 100.0%. **Rainwater Charitable Foundation's largest holding is VANGUARD TOTAL STOCK MARKET INDEX FUND-ETF** Shares with shares held of 565,280.

Whalewisdom has at least 19 13F filings

[Summary](#) [Holdings](#) [13D/G](#) [Insider \(Form 4\)](#)



03/31/2022

### Top Buys (13F)

Name	% Change
IEFA BTC iShares Core	5.9%
MS...	1.23%
VCTR Victory Capital HoL...	

03/31/2022

### Top Sells (13F)

Name	% Change
VTI VANGUARD TOTAL	6.9%
STOC...	

03/31/2022

### 13F Holdings Summary

Stock	% Port
VTI VANGUARD TOTAL	85.29%
STOCK MARKET...	7.58%
VNQ VANGUARD REAL	5.9%
ESTATE INDEX ...	
IEFA BTC iShares Core	1.23%

# together • COVID-19 trial : Dr Craig R. Rayner

clinical trials

Senior Investigator



Dr Craig R. Rayner

Simcyp Simulator (PBPK)  
Cooperative Research and Development Agreement (CRADA)

	<p>Adjunct Associate Professor Dept. Pharmaceutical Science</p>	

	<p>Medicines Development for Global Health</p>

Funder


Funder


Funder/Partnership


<p>Early Career</p>		
---------------------	--	--

	<p>DEVELOPING MEDICINES THAT MATTER™</p>
<p>CEO</p>	

	<p>President &amp; Shareholder Integrated Drug Development and Strategic Consulting Services</p>	

<p>Medical Research Future Fund</p>
<p>Funder</p>

<p>Chair of Development Committee Medical Countermeasures Products Australia (MCPA)</p>
<p>Funder</p>

# together • COVID-19 trial : Dr Francois Venter

clinical trials

**Principal Investigator**



**Dr Francois Venter**

**Funding Agencies**

**Unitaid**

**Viiiv Healthcare**

**COHIVE: Coronavirus Outcomes in HIV Evaluation**

**ADVANCE Trial US\$ 22,851,279**

**COVER HCW COVID-19 PROTECTION TO ENSURE RESILIENT HEALTH CARE WORKERS**

**Wits Reproductive Health and HIV Institute**

**University of the Witwatersrand WITS RHI**

**Ezintsha**

**Director**

**ACTaccelerator ACCESS TO COVID-19 TOOLS**

**World Health Organization**

**Advisor**

**UNAIDS**  
Joint United Nations Programme on HIV/AIDS  
UNICEF • UNDP • UNFPA • UNDCP  
UNESCO • WHO • WORLD BANK

**Advisor**

**World Health Organization**

**Funder**

**WELLCOME** **CLIFF** **CHILDREN'S INVESTMENT FUND FOUNDATION**

**BILL & MELINDA GATES foundation** **TCI Fund Management** **Google**  
**Microsoft** **WORLD ECONOMIC FORUM**

**Growing up in a digital world 2030** **FT**  
GOVERNING HEALTH FUTURES  
THE LANCET & FINANCIAL TIMES COMMISSION  
**THE LANCET** **FINANCIAL TIMES**

**CDC**  
CENTERS FOR DISEASE CONTROL AND PREVENTION  
**Funder**

**PEPFAR**  
**Funder**

**The ROCKEFELLER FOUNDATION**  
**Funder**

**NIH** National Heart, Lung, and Blood Institute  
**Funder**

**FIND**  
Because diagnosis matters  
**Funder**

**BILL & MELINDA GATES foundation**  
**Funder**

**gsk** **SOUTHERN AFRICAN HIV CLINICIANS SOCIETY** **Cipla**  
**MSD** **fhi360** **Aids Fonds**  
**THE ALUMINUM** **ANOVA HEALTH INSTITUTE**  
**MTN** **SECTION 27**  
**Bright to care** **GILEAD**

**Roche** **adcock ingram** **SANOFI**  
**Empowering Life**

**Johnson & Johnson** **aspEN**  
**PHARMACEUTICALS**

**Mylan** **MERCK**  
**Viiiv Healthcare** **GILEAD**

**Abbott** **virology education**

**Personal Fees/Support**

**UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT** **USAID** **NIH** National Institutes of Health **BILL & MELINDA GATES foundation**

**saMRC** **Sida** **NIH** Fogarty  
advancing life SWEDISH INTERNATIONAL DEVELOPMENT COOPERATION AGENCY

**Carnegie CORPORATION OF NEW YORK** **aidsfonds** **Viiiv Healthcare**

**Research Funding**

**New Partnership for Africa's Development Planning and Coordinating Agency**  
**WELLCOME** **HM Government**  
**NEPAD** **TRANSFORMING AFRICA**

**VIATRIS** Mylan+Upjohn  
**Johnson & Johnson**  
**GILEAD**  
**abbvie** **Janssen**  
**Sponsors**  
**virology education**  
**INTEREST 2015 Conference**  
**Presenter**  
**The Global Fund** To Fight AIDS, Tuberculosis and Malaria  
**PEPFAR** **MSD** **ANOVA HEALTH INSTITUTE**


**SFH** **psi** **HIV SELF-TESTING AFRICA INITIATIVE** **CLINTON HEALTH ACCESS INITIATIVE**  
**LSTM** **The STAR Initiative consortium** **ILO**  
**LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE** **World Health Organization** **PATH**  
**Advisor/Funder**



**And then there was ...**

**Andrew**

# together • COVID-19 clinical trials : Dr Andrew Hill – Conflicts of Interest





**together • COVID-19 trial : Dr Andrew Hill – Conflicts of Interest**

**World Tribune**  
WINDOW ON THE REAL WORLD



GREATEST HITS

AFRICA / EUROPE ▾

COLUMNISTS ▾

MIDEAST ▾

NE ASIA ▾

AMER

LIFE

COMMENTARY

VIDEOS

FUNNIES

SWAMP WATCH

TECH WATCH

MARKET WATCH

MEDIA

# Researcher Andrew Hill's conflict: A \$40 million Gates Foundation grant vs a half million human lives

<https://www.worldtribune.com/researcher-andrew-hills-conflict-a-40-million-gates-foundation-grant-vs-a-half-million-human-lives/>

## **A Collaboration of Funders:**


**There are currently 20 contributing partners to the Collaborative Fund, including:**

- **World Health Organization**
- **Rockefeller Foundation**
- **Ford Foundation**
- **Stephen Lewis Foundation**
- **Johnson & Johnson**
- **UNAIDS**
- **Levi Strauss Foundation**
- **AIDS Fonds Netherlands**
- **Open Society Institute**
- **Pfizer Foundation**
- **Overbrook Foundation**
- **American Jewish World Services**
- **Pfizer Foundation**
- **Tides Foundation donors**

together•COVID-19 : Dr Andrew Hill/Prof Andrew Owen – Conflicts of Interest  
clinical trials

### Funders


Remdesivir  
  
 Consultant



**Editor of Andrew Hill paper on Ivermectin**

**World Health Organization**  
 Scientific Advisor  
 COVID-19 Guideline Development Group

**Unitaid**  
 Innovation in Global Health

**UNIVERSITY OF LIVERPOOL**  
 Professor of Pharmacology & Therapeutics

**BILL & MELINDA GATES foundation**  
 Scientific Advisor

**Funding Partners**

	<b>Co-Director Centre of Excellence in Long-acting Therapeutics (CELT)</b>			

**£3million**

**Tandem Nano Ltd**  
 Solid Drug Nanoparticle technology  
 VIR-7831 and VIR-7832, novel therapies COVID owned by  
  
 Director & CSO & shareholder

Lead Molnupiravir Trial

<b>Nitazoxanide</b>			

**AGILE Clinical Team**

<b>LONGEVITY CELT</b>		


**Principal Investigator**

**£2.2 million**

As for the ...



**MHRA**  
Regulating Medicines and Medical Devices



Medicines & Healthcare  
products  
Regulatory Agency

**Table 1** How the regulators compare

	Australia TGA	Europe EMA	UK MHRA	Japan PMDA	USA FDA	Canada HC
Budgets and fees						
Proportion of budget derived from industry <sup>o</sup>	96%	89%	86%	85%	65%	50.5%
Total annual budget <sup>f</sup>	AU\$170m (€95m)	€386m (€331m)	£159m	¥29.1bn (€175m)	US\$6.1bn (€5bn)	C\$2.7bn (€1.7bn)
Transparency, COIs, and data						
Proportion of covid-19 vaccine committee members that declared financial COIs	50%	3%	32%	75%	<10%	0%
Declared COIs available as public information	No	Yes	Yes	Yes	Yes	No
Regulator routinely receives patient level datasets*	No	No	No	Yes	Yes	No
Drug approvals						
Proportion of decisions to approve new medicines (v not approve)	94%	88%	98.5%	Not disclosed	69% <sup>^</sup> 29% <sup>#</sup>	83%
Proportion of new drugs approved through expedited pathways in 2020	20%	50%	36% <sup>f</sup>	26%	68%	16%

Note: Data sources and methods are detailed in the supplemental file

<sup>f</sup>Data refer to the year 2021 calendar year or 2020-2021 fiscal year

<sup>o</sup> Many agencies regulate beyond medical products (for example, food); where possible (US, Canada), we used the proportion of the human drugs budget

FDA: US Food and Drug Administration; EMA: European Medicines Agency; TGA: Therapeutic Goods Administration; HC: Health Canada; MHRA: Medicines and Healthcare Products Regulatory Agency; PMDA: Pharmaceuticals and Medical Devices Agency

Feature » BMJ investigation

### From FDA to MHRA: are drug regulators for hire?

BMJ 2022 ; 377 doi: <https://doi.org/10.1136/bmj.o1538> (Published 29 June 2022)

Cite this as: BMJ 2022;377:o1538

Article

Related content

Metrics


Responses

Maryanne Demasi, investigative journalist

**“Like the FDA, the TGA was founded to be an independent institute. However, being largely funded by fees from the companies whose products it is charged to evaluate is a fundamental conflict of interest and a prime example of institutional corruption.”**

**Donald Light**  
Sociologist  
Rowan University  
New Jersey

# Medicines & Healthcare products Regulatory Authority, UK and Conflicts of Interest







Medicines & Healthcare  
products  
Regulatory Agency

# Conflicts of Interest

FOI release

## Freedom of Information request about the Bill and Melinda Gates Foundation (FOI-21-509)

Published 28 June 2021

Thank you for your email.

We do receive funding from the Bill and Melinda Gates Foundation as well as other sources outside government such as WHO. This funding mainly supports work to strengthen regulatory systems in other countries.

The majority of our income comes from the pharmaceutical industry through fees. For example, all Marketing Authorisation applicants have to pay a fee. The licensing of medicines is an independent, scientific process which is overseen by the Commission on Human Medicines (CHM).

Grant topic	Date	Committed amount
Family Planning	AUGUST 2021	\$251,377
Enteric and Diarrheal Diseases	AUGUST 2020	\$855,573
Pneumonia	JUNE 2020	\$521,225
Development of Solutions to Improve Global Health	AUGUST 2019	\$945,033
Enteric and Diarrheal Diseases	JUNE 2018	\$48,647
Pneumonia	MARCH 2018	\$375,710
Development of Solutions to Improve Global Health	OCTOBER 2017	\$3,008,530
Discovery and Translational Sciences	NOVEMBER 2011	\$3,681,701



CONTRACT AWARDS 

Provision of Services to Generate the First International Standard Serum for the Quantification of Shigella Antibodies

*Bill & Melinda Gates Foundation (B&MGF)*

Provision of Services to Prepare International Group B Streptococcus (GBS) Polysaccharides and Human Reference Standards

*Bill & Melinda Gates Foundation (B&MGF)*

Evaluate the Use of Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulations

*Bill & Melinda Gates Foundation (B&MGF)*

Provision of Access to Global Health Solutions

*Bill & Melinda Gates Foundation (B&MGF)*

Provision of Improved Access to Global Health Solutions

*Bill & Melinda Gates Foundation (B&MGF)*

Provision of Access to Global Health Solutions

*Bill & Melinda Gates Foundation (B&MGF)*

Advance O-antigen-based Shigella Vaccines Through Licensure by Providing Data on Immunogenicity

*Bill & Melinda Gates Foundation (B&MGF)*

Developing the First International Standard for Influenza Hemagglutinin (HA) Stalk Based Antibody to Accelerating Universal Flu Vaccine Development

*Bill & Melinda Gates Foundation (B&MGF)*

To Build Sustainable Capacity In Pharmacovigilance In The Low And Middle Income Country Settings

*Bill & Melinda Gates Foundation (B&MGF)*

# Medicines & Healthcare products Regulatory Authority (MHRA) Board Declarations of Interest – May 2022

Name and MHRA Role	Conflicts of Interest	Nature of interest	Paid
<b>Stephen Lightfoot</b> Chair of Board	1. NHS Sussex Integrated Care Board 2. Sussex Primary Care Limited	Chair Designate Chair and Director	Yes No
<b>Dame Dr June Raine</b> Chief Executive Officer	WHO Committee on Safety of Medicinal Products European Pharmacovigilance Risk Assessment Committee on behalf of the European Medicines Agency	Member Chair	No No
<b>Dr Marc Bailey</b> Chief Scientific Officer	Nokia Corporation	Ex-employee shareholder	No
<b>Dr Junaid Bajwa</b> Non-Executive Director	1. Microsoft 2. Merck Sharp and Dohme 3. Novartis Industry Council 4. Ondine Biomedical 5. Nahdi Medical Corporation 6. UCLH 7. Whittington NHS Trust 8. Nuffield Health	Chief Medical, Shareholder Ex-employee shareholder Advisory to UK Pharma Exec Non-Executive Director Non-Executive Director Non-Executive Director Associate Non-Executive Director Governor (NED)	Yes No Yes Yes Yes Yes Yes Yes
<b>Amanda Calvert</b> Non-Executive Director	1. Astrazeneca 2. Quince Consultancy Ltd 3. Athenex Pharma 4. University of Manchester Digital Experimental Cancer Medicine Team	Ex-employee shareholder Immediate family member Provides consultancy services including companies in the healthcare sector. Consultancy on oral oncology chemotherapy platform. Providing strategy and data protection consultancy	No Yes Yes Yes

## Medicines & Healthcare products Regulatory Authority (MHRA) Board Declarations of Interest – May 2022

Name and MHRA Role	Conflicts of Interest	Nature of interest	Paid
<b>Dr Paul Goldsmith</b> Non-Executive Director	1. Closed Loop Medicine Ltd	Shareholder, director & employee; ILAP applicant	Yes
	2. Summit Inc	Shareholder	No
	3. Ieso Digital Health	Director, Shareholder	Yes
	4. MDU Ltd	Director, Shareholder	No
	5. MDU Investments Ltd	Director	Yes
	6. NHS	Consultant Neurologist	Yes
<b>Professor Graham Cooke</b> Non-Executive Director and Deputy Chair	1. Sanofi CoV	Chair of End Point Review Committee for vaccine trial	Yes
	2. Seventh Sense Biosystems	Consultant/Advisor	Yes
	3. 30 Technology Ltd	Consultant/Advisor	Yes
	4. DNAnudge Ltd	Consultant/Advisor	No
	5. Debevoise and Plimpton LLP	Consultant/Advisor in relation to COVID protocols	Yes
	6. WHO	Chair of Committee for Selection and Use of Essential Medicines	No
	7. NIHR	NIHR Research Professor	Yes
<b>Haider Husain</b> Associate Non-Executive Director	1. Healthinnova Limited	Chief Operating Officer	Yes
	2. Milton Keynes University Hospital	Non-Executive Director	Yes
	3. NHS Foundation Trust		
	4. British Standards Institute	Panel Chair BS30440 – Use of AI within Healthcare	No
	5. Microsoft Corp	Shareholder	Yes
	6. BBC	Family Member	No

## Medicines & Healthcare products Regulatory Authority (MHRA) Board Declarations of Interest – May 2022

Name and MHRA Role	Conflicts of Interest	Nature of interest	Paid
<b>Raj Long</b> Non-Executive Director	<ol style="list-style-type: none"> <li>1. Gates Foundation</li> <li>2. Bristol-Myers Squibb</li> <li>3. Novartis</li> <li>4. RESOLVE (Sustainable solutions to critical social, health, and environmental challenges)</li> <li>5. EC IMI NEURONET EC Innovative Medicines Initiative (IMI) Non-Product</li> <li>6. Gates Venture – EC Innovative Medicines Initiative (IMI) Non-Product – IMI European platform for Neurodegenerative Disorders</li> <li>7. HUYA Bio Access</li> <li>8. WHO – Sustainable</li> <li>9. UK Health Security Agency</li> </ol>	Employee, Deputy Director Ex-Employee Shareholder Ex-Employee, Shareholder Scientific Advisory  Scientist Advisory Board Scientific Advisory Advisory Advisory Expert COVAX Manufacturing Strategy for Regional Health Security Associate Non-Executive Board Member	Yes Yes Yes No  No Yes Yes No  Yes

# Medicines & Healthcare products Regulatory Authority (MHRA) Board Declarations of Interest – May 2019-2021

Name and MHRA Role	Conflicts of Interest	Nature of interest	Paid
<p><b>Sir Michael Rawlins</b> Former Chair</p>	<ol style="list-style-type: none"> <li>1. Intra-Cellular Therapies</li> <li>2. The London School of Hygiene and Tropical Medicine</li> <li>3. National Institute for Clinical Excellence (NICE)(Bill and Melinda Gates Foundation Rockefeller Foundation)</li> <li>4. Royal Society of Medicine (UK)</li> <li>5. Knight Grand Cross of the Order of the British Empire (GBE)(2017)</li> <li>6. Hereditary Disease Foundation (Roche, Sanofi, Novartis, Genentech, Teva)</li> <li>7. Wellcome Trust</li> <li>8. Medical Research Council (UK)</li> </ol>	<p>Independent Director Honorary Professor Founding chairman President</p> <p>Funding Funding Funding</p>	<p>Yes No</p>
<p><b>Professor David Webb</b> Deputy Chair of the Board</p>	<ol style="list-style-type: none"> <li>1. Idorsia</li> <li>2. British Heart Foundation</li> <li>3. British Pharmacological Society</li> <li>4. Wellcome Trust</li> </ol>	<p>UK Clinical Investigator, Precision Trial Clinical trial and project grants Honorary Fellow, Past President and Organiser, WCP2022 Funding</p>	<p>No</p>
<p><b>Dr Ian Hudson OBE</b> Chief Executive Former Licensing Director</p>	<ol style="list-style-type: none"> <li>1. GlaxoSmithKline</li> <li>2. Sensyne Health plc (Clinical AI company)</li> <li>3. Bill and Melinda Gates Foundation</li> <li>4. UKCRC Clinical Trials Unit Network NIHR</li> </ol>	<p>Former Project Manager Non-Executive Director Senior Advisor, Integrated Development. Global Health Chair of the International Review Panel for clinical trial accreditation</p>	<p>Yes Yes Yes Yes</p>

# National Institute for Biological Standards and Control (NIBSC) Scientific Advisory Committee (2022 – 2023)

Name and MHRA Role	Conflicts of Interest	Nature of interest	Paid
<p><b>Professor David Webb</b> Committee Chair and MHRA Deputy Chair of the Board</p>	<ol style="list-style-type: none"> <li>1. Idorsia</li> <li>2. British Heart Foundation</li> <li>3. British Pharmacological Society</li> <li>4. Wellcome Trust</li> </ol>	<p>UK Clinical Investigator, Precision Trial Clinical trial and project grants Honorary Fellow, Past President and Organiser, WCP2022 Funding</p>	
<p><b>Professor Andrew Pollard</b> Advisory Member</p>	<ol style="list-style-type: none"> <li>1. Joint Committee on Vaccination and Immunisation (JVCI)</li> <li>2. Oxford-Jenner AstraZeneca Sars-coV-2 Vaccine Trial</li> <li>3. WHO's Strategic Advisory Group of Experts</li> <li>4. Medicines and Healthcare Products Regulatory Agency (MHRA)</li> <li>5. European Medicine Agency (EMA)</li> <li>6. Scientific Advisory Group on Vaccines at the European Medicines Agency</li> <li>7. National Institute for Health and Care Excellence (NICE)</li> <li>8. Oxford Vaccine Group</li> <li>9. Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK</li> <li>10. Bill &amp; Melinda Gates Foundation</li> <li>11. Coalition for Epidemic Preparedness Innovations (CEPI)</li> </ol>	<p>Chair Chief Investigator Board member Former Senior Advisor Member Panel, Advisor Chair Chair Director Lead developer  Funding Funding</p>	
<p><b>Professor Paul Kellam</b> Advisory Member</p> <p><a href="https://www.nibsc.org/about_us/scientific_advisory_committee.aspx">https://www.nibsc.org/about_us/scientific_advisory_committee.aspx</a></p>	<ol style="list-style-type: none"> <li>1. Scientific Advisory Group for Emergencies in response to COVID-19</li> <li>2. Dept. Virus Genomics, Imperial College London</li> <li>3. Infectious diseases &amp; vaccines at Kymab Ltd, a Sanofi company</li> <li>4. Dept. Virus Genomics at Wellcome Trust Sanger Institute</li> <li>5. Vaccines Taskforce, secondment contract to BEIS from Imperial College London</li> <li>6. Excalibur Health</li> <li>7. Academic Health Solutions International Advisory Panel</li> <li>8. RQ Biotechnology Ltd</li> </ol>	<p>Member Professor Vice President Lead Researcher Scientific Adviser  External consultant Ad-hoc Consultant, Member Founder, Shareholder</p>	<p>No Yes Yes Yes Yes  Yes Yes Yes</p>



# Joint Committee on Vaccination and Immunisation (JCVI), UK and Conflicts of Interest

## Advises UK Health Departments on Vaccination

Committee Member	Disclosed and Undisclosed Interests	Funding and Grants
Professor Andrew Pollard (Chair JCVI)	<ol style="list-style-type: none"> <li>1. Recused himself from all JCVI COVID-19 meetings</li> <li>2. Chief Investigator - Oxford-Jenner AstraZeneca Sars-coV-2 Vaccine Trial</li> <li>3. WHO's Strategic Advisory Group of Experts board member</li> <li>4. Chair - National Institute for Health and Care Excellence (NICE)</li> <li>5. Director of the Oxford Vaccine Group</li> </ol>	Partnership AstraZeneca
Professor Maarten Postma (University of Groningen)	<ol style="list-style-type: none"> <li>1. Infect Dis Ther. 2018 Sep;7(3):353-371. Contributing author</li> <li>2. Infect Dis Ther. 2019 Mar; 8(1): 1-3.. Contributing author</li> <li>3. Expert Review of Vaccines, Volume 11, 2012 - Issue 10</li> <li>4. Lancet. 2021 Aug 7; 398(10299): 503-521</li> <li>5. Received grants, honoraria from all companies developing, producing, and marketing non-vitamin K oral anticoagulants (NOACs)</li> <li>6. Independently received Grants, Honouria, personal fees</li> <li>7. Shareholder in pharmacology company</li> <li>8. Adviser to the consultancy company</li> </ol>	<p>Funded by Pfizer. Received grants and honouria from Pfizer Pfizer paid consultant</p> <p>Funded by Pfizer Bill &amp; Melinda Gates Foundation Boehringer Ingelheim, Pfizer, Bayer, Daiichi-Sankyo and Bristol-Myers Squibb GSK, Astra Zeneca, Biomarin, MSD, Merck, Sanofi, Novartis, Novavax, BMS, IQVIA, Seqirus; Quintiles, Novartis, Pharmedit, Bayer, DIKTI, LPDP, Budi, WHO, Antilope, FIND, EU, and BioMerieux Holds stocks Ingress Health and Pharmacoconomics Advice Groningen (PAG Ltd), Health-Ecore Asc Academics</p>
Professor Anthony Scott (Director of the Health Protection Research Unit - London School of Hygiene & Tropical Medicine)	<ol style="list-style-type: none"> <li>1. Wellcome Trust Senior Research Fellow in Clinical Science</li> <li>2. He receives research funding from the National Institute for Health Research, the Medical Research Council, the Wellcome Trust and Gavi, The Vaccine Alliance, and the Bill &amp; Melinda Gates Foundation.</li> <li>3. London School of Hygiene &amp; Tropical Medicine (employer)</li> </ol>	\$308,640,471

# Joint Committee on Vaccination and Immunisation (JVCI), UK and Conflicts of Interest

## Advises UK Health Departments on Vaccination

Committee Member	Disclosed and Undisclosed Interests	Funding and Grants
<p>Prof Lim Wei Shen (Chair, Nottingham University Hospitals)</p> <p>Appointed Chair of the JCVI sub-committee on COVID-19 vaccines (Prof Andrew Pollard recused himself – perceived conflict of interest)</p>	<ol style="list-style-type: none"> <li>Chief Investigator in research study funded by</li> <li>Co-investigator of the NIHR-funded (COVID19) RECOVERY Trial</li> <li>Expert Panel Member: NICE COVID19 Guidelines</li> <li>Member of UK Specialist Commissioning Group – Remdesivir, Tocilizumab</li> <li>Nottingham University</li> </ol>	<p>Pfizer. £25,001 (2021)</p> <p>National Institute for Health Research, UK MRC Wellcome Trust, Gates Foundation. AbbVie, Regeneron, Roche</p> <p>\$13,510,155 (Gates Foundation)</p>
<p>Prof Anthony Harnden</p> <p>Deputy Chair (University of Oxford)</p>	<ol style="list-style-type: none"> <li>Partner at an Oxfordshire Practice which is a PCN lead practice for COVID- 19 vaccine administration.</li> <li>Member of the Covid-19 Vaccine Deployment Clinical Review Group</li> <li>University of Oxford</li> </ol>	<p>\$278,724,831 (Gates Foundation)</p>
<p>Dr Kevin Brown</p>	<ol style="list-style-type: none"> <li>Public Health England</li> <li>Co-authored favourable study on the “real world effectiveness” of the Pfizer &amp; AZ jabs</li> </ol>	<p>\$7,451,295 (Gates Foundation)</p>
<p>Professor Adam Finn</p> <p>(University of Bristol)</p>	<ol style="list-style-type: none"> <li>Chief investigator in the Valneva COVID19 vaccine clinical trials programme in the UK and in the Sanofi COVID19 booster vaccine clinical trial in the UK</li> <li>Principal or Co-investigator in the Oxford-Astra Zeneca COV001, COV002 and COV006 studies and the National Immunisation Schedule Evaluation Consortium study ComFluCov.</li> <li>Detecting SARS-CoV-2 variants</li> <li>Study grant from GlaxoSmithKline (GSK)</li> <li>Head of Pfizer Vaccine Centre of Excellence at the University of Bristol</li> <li>Chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE)</li> </ol>	<p>Pfizer, Sanofi-Aventis, Gates Foundation</p> <p>AstraZeneca. Janssen</p> <p>Wellcome Trust</p> <p>£4.6 million (Pfizer)</p>



## OUR ACCOMPLISHMENTS

BARDA's mission is accomplished through successful public-private partnerships with industry to share risk, improve efficiency, and accelerate development all while sustaining a marketplace that guarantees continued access to the vaccines, therapeutics, diagnostics, and other medical products that are vital to our national health security.

**BARDA's Programs** →]



### Partnerships

Over 500 public-private partnerships established



### Delivered

countermeasures in response to H1N1, Ebola, and Zika



### Explore →]

for 63 products receiving FDA approval, clearance, or licensure

## Products

## Products

Biotherapeutics ▶

Diagnostics ▶

Vaccines ▼

## Coronavirus (V)

Botulinum

Clostridium

Diphtheria

Emerging Viruses (V)

Enteric disease

Haemophilus Influenzae type  
b (Hib)

Human Papillomavirus

Influenza

Search

You are currently viewing the Coronavirus (V) in the Vaccines category

**Product number:**

0688

**Description:**

SARS CoV-1 spike S1 protein

Add to cart

[Product details](#)**Product number:**

100976

**Description:**

pCAGGS-SARS-CoV-2-Spike

Add to cart

[Product details](#)**Product number:**

100978

**Description:**

VeroE6/TMPRSS2

Add to cart

[Product details](#)**Product number:**

100980

**Description:**

SARS-CoV-2 infectious virus (BetaCoV/Australia

Add to cart

[Product details](#)

/MIC01/2020



## 3.7 Intellectual Property

- 3.7.1 In the case of NIBSC, the Agency will file patent applications for inventions where the intellectual property has the potential to provide benefit to public health, and to be novel. Where there is no COI with the Agency's regulatory role, the Agency will own and exploit the intellectual property. Intellectual property may be developed that may lead to a new medicinal product; in such cases, the intellectual property will be divested to another organisation within eighteen months of the filing of a patent application, or promptly thereafter should a therapeutic potential be established.
- 3.7.2 IP is often created during CPRD developmental projects. When IP for the benefit of CPRD is created, steps will be taken to ensure its ownership is secured for the Agency and any necessary rights are established. IP is held in the name of the 'MHRA'. When CRPD develops IP for the benefit of a client in the course of a commissioned research study, the arising IP is generally owned by the commissioning organisation, in accordance with normal research practice. In such cases, the IP becomes the property of the client, while background IP (the source CPRD data) remains the property of the Agency. This is clearly set out in CPRD research study contracts.

# Scientific Advisory Group for Emergencies (SAGE), UK: Major Conflicts of Interest



# UK SAGE Conflicts of Interest

## HOW 'INCESTUOUS' CAN IT GET!



Sir Patrick Vallance


- \* Chief Scientific Adviser, UK Government (2018 – present)
- \* Chair of Scientific Advisory Group for Emergencies (SAGE) (2020 – present)
- \* Chair Pandemic Preparedness Partnership (UK), joint public-private-partnership with Gates funded CEPI (2021 – present)
- \* Head of UK Vaccine Taskforce (2021 – present)

- \* Former President of GlaxoSmithKline (2012-2017)
- \* £600,000 shares in GlaxoSmithKline
- \* UK government signs coronavirus vaccine deal with GlaxoSmithKline (July 2020)
- \* GSK-Gates Foundation partnership (2013) to 'accelerate vaccine research for global health needs



Prof Chris Whitty

- \* Chief Medical Officer, UK
- \* Executive Board of the World Health Organization
- \* Professor of Public and International Health London School of Hygiene and Tropical Medicine (LSHTM)
- \* Received £31million in funding from the Bill and Melinda Gates Foundation for malaria research



Prof Jonathan Van-Tam

- \* Deputy Medical Officer, UK
- \* Chair New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)
- \* UK Vaccine Taskforce advisor
- \* Advisor to the World Health Organisation
- \* Associate director SmithKline Beecham (now GSK, 2000)
- \* Head of Medical Affairs at Roche (2001)
- \* Aventis Pasteur MSD UK medical director (2002)

# SOUTH AFRICA INC.



WORLD  
ECONOMIC  
FORUM



World Health  
Organization

# “DOG”




# South African Ministerial Advisory Committee on COVID-19 and Conflicts of Interest

Researcher	Institution	Role in MAC	Sub Funder	Principal Funder
<b>Prof Salim Abdool Karim</b>	CAPRISA	OVER-ARCHING CHAIR	USAID via Concord WHO TB-HIV task force	Bill and Melinda Gates Foundation (BMGF)
Prof Quraisha Abdool Karim	CAPRISA	Public Health		BMGF
<b>Prof Helen Rees</b>	South African Health Products Regulatory Authority (SAHPRA)	Clinicians	WHO, Co-Chair Ebola Vaccine	BMGF
Prof Lynn Morris	National Institute for Communicable Diseases (NICD)	Pathologists and Laboratory		BMGF
Prof Wolfgang Preiser	National Health Laboratory Service	Pathologists and Laboratory		BMGF
Prof Wendy Stevens	National Health Laboratory Service	Pathologists and Laboratory		BMGF
<b>Prof Shabir Madhi</b>	SAMRC	CHAIR, Public Health	WHO, Consultant	BMGF, Consultant
<b>Prof Glenda Gray</b>	SAMRC	CHAIR, Research	NIH, Wellcome Trust	BMGF
<b>Prof Marc Mendelson</b>	University of Cape Town	CHAIR, Clinicians	WHO	BMGF
Dr Moherndran Archary	University of KwaZulu-Natal	Clinicians		BMGF
Prof Shabir Banoo	Right to Care	Clinicians	WHO	BMGF

# The Bill and Melinda Gates Foundation SA Team:

## South African Ministerial Advisory Committee on Vaccines



# SAHPRA

South African  
Health Products  
Regulatory Authority

## ANNUAL

# REPORT 2019/20

---

This flagship programme (Backlog Project) is supported by the **Bill and Melinda Gates Foundation** whose insight into the importance of SAHPRA's re-engineering project and confidence in SAHPRA's ability to transform has been unstinting.



Chairperson of the Board  
Prof. Helen Rees  
Date: 30 October 2020

# Covid Vaccines: Conflict of Interests – Prof Helen Rees



“

We started a backlog project with a big grant from the **Bill & Melinda Gates Foundation**, which was essential...

**Prof. Helen Rees**

Chairperson: SAHPRA

## Backlog Budget

BACKLOG	2018/19	2019/20	2020/21	2021/22	TOTAL
<b>REVENUE</b>					
Treasury Allocation		10 000 000	20 000 000		30 000 000
Treasury Allocation		30 000 000			30 000 000
Sahpra Revenue from fees	35 000 000				35 000 000
Centers for Disease Control and Prevention (CDC) - Donor funding		24 000 000	0	0	24 000 000
Bill and Melinda Gates Foundation - Donor funding		12 500 000	25 000 000	12 500 000	50 000 000
Clinton Health Access Initiative (CHAI) - Donor funding	1 400 000				1 400 000
					-
<b>TOTAL REVENUE</b>	<b>36 400 000</b>	<b>76 500 000</b>	<b>45 000 000</b>	<b>12 500 000</b>	<b>170 400 000</b>
<b>EXPENDITURE</b>	<b>2018/19</b>	<b>2019/20</b>	<b>2020/21</b>	<b>2021/22</b>	<b>TOTAL</b>
Compensation of employees		7 066 667	10 600 000	7 066 667	24 733 333
External Evaluators (Domestic)		16 950 000	33 900 000	16 950 000	67 800 000
External Evaluators (International)		46 125 000	92 250 000	46 125 000	184 500 000
Goods & Services		6 075 000	12 150 000	6 075 000	24 300 000
Digital/IT		1 025 000	2 050 000	1 025 000	4 100 000
Total Expenditure	-	77 241 667	150 950 000	77 241 667	305 433 333
Surplus/shortfall	36 400 000	- 741 667	-105 950 000	- 64 741 667	-135 033 333



BILL & MELINDA  
GATES foundation





## GRANT

← BACK

 Print

### Wits Health Consortium

---

**Date:** June 2019

**Purpose:** to work with SAHPRA by hiring external international experts at SAHPRA's request who will undertake the assessment of specific backlog applications under SAHPRA's oversight

**Amount:** \$3,140,019

**Term:** 30

**Topic:** Development of Solutions to Improve Global Health

**Regions Served:** GLOBAL|AFRICA

**Program:** Global Health

**Grantee Location:** Johannesburg, Gauteng

**Grantee Website:** <https://www.witshealth.co.za/>

**WHO expert advisor**  
 Chair: International Health Regulation Polio Emergency Committee



**World Health Organization**

International Health Regulation Emergency Committee on COVID-19

**SAGE Working Group on COVID-19 vaccines**

Co-Chair SAGE WORKING GROUP ON EBOLA VACCINES & VACCINATION

African Regional Immunisation Technical Advisory Group on Immunization (RITAG)

SAGE Measles and Rubella Working Group

**BILL & MELINDA GATES foundation**


Chair: Bill & Melinda Gates Foundation Committee on Single Dose HPV vaccines

**SAHPRA**  
 South African Health Products Regulatory Authority

SAHPRA Chairperson

**CLINTON HEALTH ACCESS INITIATIVE**

**CDC**  
 CENTERS FOR DISEASE CONTROL AND PREVENTION



**Prof Helen Rees, OBE**

**WITS HEALTH CONSORTIUM**

Executive Director

**WITS VIDA**  
 UNIVERSITY OF THE WITWATERSRAND  
 VACCINES & INFECTIOUS DISEASES ANALYTICS

**UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG**

**Gavi**  
 The Vaccine Alliance

Chair: the Gavi Programme and Policy Committee and Board Member

**COVAX**

Oversight Committee

**CEPI**  
 Coalition for Epidemic Preparedness Innovations

Chair: CEPI Scientific Advisory Committee



Order of the British Empire, OBE, by Queen Elizabeth II (2001)




Grand Counsellor, Order of the Baobab

**Alive**  
 AFRICAN LEADERSHIP IN VACCINOLOGY EXPERTISE

ALIVE Co-Chair

**saMRC**  
 advancing life

Former Chairperson





University of the Witwatersrand  
WITS RHI

# Wits Reproductive Health and HIV Institute and Prof Helen Rees

## Conflicts of Interest



Founder & Director  
of Wits RHI

## Donors & Partners



THE AURUM  
INSTITUTE



UNIVERSITY OF THE  
WITWATERSRAND  
JOHANNESBURG





19 09 LIVE

# Karim gets his reward?


WORLD HEALTH ORGANIZATION

PROF. SALIM ABDOOL KARIM

WHO  
SCIENCE PANEL

WATCHING eNCA ON DSTV CHANNEL 403 | PLEASE SEND PICS AND VIDEOS TO [pictures@enca.com](mailto:pictures@enca.com) OR [upload.e](#)

# Prof Salim Abdool Karim: A 'Global Élite' Puppet



Prof Salim Abdool Karim

**Director and co-Founder**

**Former President and CEO**

**Scientific Advisor**

**Fellow of the Royal Society (FRS)**

**Chair: UNAIDS Scientific Expert Panel**

**Professor of Global Health**

**MRC HIV-TB Pathogenesis and Treatment Director**

**South African Ministerial Advisory Committee on COVID-19 Over-Archiving Chair**

**Pro-Vice-Chancellor**

**Adjunct Professor**

**Associate**

**Advisor**

**Consultant**

**Funders**

**WHO Science Council HIV and Hepatitis Scientific and Technical Advisory Group**  
**WHO HIV-TB Task Force Chair of the Scientific and Technical Advisory Group for Reproductive Health**

**Editorial Board**

**Commissioner**

**Scholarship, 1987**

**Masters Scholarship, 1987**

**Studied, 1988**

**Board Member**

**Editorial Board**

# What Big Pharma pays Medical Journal Editors


Table: List of journals, editors eligible for Open Payments,\*† and industry payments‡ reported in Open Payment database, 2014

Journal	No Editors	General Payment (\$)	Research Payment (\$)
Journal of the American Medical Association (JAMA)	31	6331 (18 084)	84 516 (325 572)
Annals of Family Medicine	10	1376 (4342)	27 517 (87 015)
Pain	11	14 203 (31 094)	38 582 (101 958)
American Journal of Psychiatry	21	4410 (7770)	11 017 (26 871)
Radiology	19	11 559 (24 288)	94 920 (297 930)
Journal of the American College of Cardiology	24	475 072 (2 237 949)	119 407 (286 546)
Circulation	28	11 685 (24 001)	75 396 (235 757)
Journal of the National Cancer Institute	59	5154 (13 576)	76 223 (323 500)
Journal of Clinical Oncology	8	5957 (9474)	160 304 (307 252)
American Journal of Gastroenterology	26	24 090 (47 197)	54 454 (112 693)
Diabetes Care	14	96 688 (154 229)	212 426 (530 654)
Arthritis and Rheumatology	26	26 266 (73 037)	68 323 (129 522)

**Global Health  
Security Agenda  
Architecture**



# Global Health Security Agenda Architecture



# Global Health Security Agenda



Private  
Sector  
Roundtable

# Private Sector Roundtable on Global Health Security

## Co-Chairs of Private Sector Roundtable (PSRT)



**Dr Alan Tennenberg**

Chief Medical Officer Global  
Public Health, Johnson &  
Johnson



**Ashling Mulvaney**

Vice President, Global Sustainability,  
Access to Healthcare, AstraZeneca



**Dr. David Barash**

Chief Medical Officer and  
Executive Director of Global  
Health, GE Foundation





# GLOBAL HEALTH SECURITY AGENDA



Global Health Security  
Agenda Consortium

## Latest Work

Tech Solutions for Global Genomic Sequencing and Surveillance

[DOWNLOAD REPORT](#)

An Ambitious Proposal to Strategically Vaccinate the World Against Covid-19

[DOWNLOAD REPORT](#)

Understanding the Vaccine Absorption-Capacity Challenge

[DOWNLOAD REPORT](#)

The Case for a Global Adult-Vaccination Programme to Combat Preventable Disease

[DOWNLOAD REPORT](#)

Global Governance of Genomic Pathogen Surveillance: Opportunities and Challenges

[DOWNLOAD REPORT](#)



**World Health  
Organization**

---

**Conflicts of Interests?**





**H.E. Dr Gro Harlem Brundtland**

Co-Chair, GPMB; Former Prime Minister, Norway and Former Director-General, World Health Organization Bilderberger (1983)



**Mr Elhadj As Sy**

Co-Chair, GPMB, Secretary-General, International Federation of Red Cross and Red Crescent Societies Wellcome Trust



**H.E. Dr Diane Gashumba**

Minister of Health, Republic of Rwanda



**H.E. Sigrid Kaag**

Minister for Foreign Trade and Development Cooperation, The Netherlands



**Dr Victor Dzau**

President, The National Academy of Medicine, USA Director of PepsiCo (2005). Advisor NIH



**Dr Chris Elias**

President, Global Development Program, Bill & Melinda Gates Foundation, USA



**Professor Ilona Kickbusch**

Director, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland



**H.E. Professor Veronika Skvortsova**

Minister of Health, Russian Federation



**Sir Jeremy Farrar**

Director, Wellcome Trust, UK



**Dr Anthony S. Fauci**

Director, National Institute of Allergy and Infectious Diseases, USA



**Dr Yasuhiro Suzuki**

Chief Medical and Global Health Officer, Vice Minister for Health, Ministry of Health, Labour and Welfare, Japan



**Dr Jeanette Vega Morales**

Chief Medical Innovation and Technology Officer, La Red de Salud UC-Christus, Chile



**Ms Henrietta Fore**

Executive Director, UNICEF



**Dr George F. Gao**

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



**Professor K. VijayRaghavan**

Principal Scientific Advisor to the Government of India



# Voluntary contributions by fund and contributor

Contributor	(2021)	(2020)	(2019)
<b>Bill &amp; Melinda Gates Foundation</b>	<b>\$375 597 694</b>	<b>\$375 546 744</b>	<b>\$226 337 804</b>
<b>GAVI Alliance</b>	<b>\$244 540 452</b>	<b>\$187 080 008</b>	<b>\$230 120 648</b>
CDC Foundation	\$1 858 347	\$2 197 194	\$2 844 154
Clinton Health Access Initiative	\$856 492	\$444 021	\$402 343
Rockefeller Foundation	\$750 000	\$3 906 800	\$2 514 994
Grand Challenges Canada (BMGF)			
Gates Ventures, LLC	\$218 000	\$310 750	
Open Society Foundations	\$265 000	\$240 000	\$161 753
Global Antibiotic Research & Development Partnership (GARDP)	\$258 896	\$149 090	
Johnson and Johnson Family of Companies Contribution Fund, Inc.	\$14 957 229	\$600 000	
Johns Hopkins Bloomberg School of Public Health			
Path Vaccine Solutions (PVS)			\$161 753
Program for Appropriate Technology In Health (PATH)	\$972 455		\$345 500
Wellcome Trust	\$5 574 180		
Global Fund to Fight AIDS, Tuberculosis and Malaria	\$29 700 000	\$17 745 189	\$15 718 411
International Vaccine Institute (IVI)	\$317 000	\$60 000	
UNITAID	\$33 519 000	\$18 308 869	\$20 296 997
World Bank	\$38 735 962	\$93 592 671	\$74 005 754
World Organisation for Animal Health (OIE)	\$107 502		
Population Action International (PAI)	\$14 194	\$287 251	\$370 000
Rotary International	\$84 661 438	\$89 162 889	\$86 559 824

## WHO Funding

**80% from voluntary contributions**

**18% from assessed contributions**

**45% voluntary contributions (2018 – 2019) from Bill and Melinda Gates Foundation**


**Fully invested in Covid Industry**

# World Health Organisation Funding: Conflicts of Interests



Top 10 voluntary contributors (specified)

Financial Year (2018-19)



## Funding source:

Flexible funding: 94%

Voluntary contributions – specified: 6%

Of the total voluntary contributions specified, 88% were from 10 contributors (shown beside)



**Dr Tedros Adhanom  
Ghebreyesus**

**Global Elite “Prostitute”**



# Tedros Adhanom Ghebreyesus: "Prostituting himself"

 **World Health Organization**

 **The Global Fund** (2009 to 2011)

 **Gavi**  
The Vaccine Alliance

 **UNAIDS**

 **CLINTON FOUNDATION**

 **aspen institute**

 **IHME**  
Institute for Health Metrics and Evaluation

 **Harvard School of Public Health**



Fig. Bill Gates and Tedros Adhanom Gherbreyesus



Director-General Tedros Adhanom Ghebreyesus is in the WHO to do Bill Gates' bidding

# WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"



**Imperial College London**  
Senior Research Fellow  
Honorary Lecturer

Prof Neil Ferguson



**World Health Organization**

JPMORGAN CHASE & CO. Rockefeller Brothers Fund  
philanthropy for an Interdependent World

Google.org facebook. Eisai STATE STREET  
Pfizer The Pfizer Foundation  
Baxter International Foundation  
MSD INVENTING FOR LIFE

**COVID-19 Solidarity Response Fund**

gsk Johnson & Johnson GE Foundation

THE WORLD BANK  
IBRD · IDA

Bloomberg Philanthropies INSTITUT PASTEUR  
Post-Doctoral Fellow



**Dr Maria D. Van Kerkhove**  
COVID-19 Technical Lead of the World Health Organization (WHO)

DFID Department for International Development

UKRI Medical Research Council

CONSIZE  
CONSORTIUM FOR THE STANDARDIZATION OF INFLUENZA SEROEPIDEMIOLOGY

CDC  
CENTERS FOR DISEASE CONTROL AND PREVENTION

LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE  
PhD Degree



wellcome

Stanford MEDICINE  
Masters Degree



CORNELL UNIVERSITY  
FOUNDED A.D. 1865  
Undergraduate Degree

BILL & MELINDA GATES foundation

NIH Fogarty National Institutes of Health



unicef



## Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Alejandro Cravioto (Chair)	Universidad Nacional Autónoma de México, Puerto Vallarta, Mexico	Bill & Melinda Gates Foundation. Wellcome Trust. Chief Scientific Officer of International Vaccine Institute (IVI). Executive Director. International Centre for Diarrhoeal Disease Research (icddr, USAID, NIH. CDC. Global Fund)
Dr Hanna Nohynek (Vice-Chair)	Chief Physician, Finnish Institute for Health and Welfare (Thl), Helsinki, Finland	Bill & Melinda Gates Foundation. PATH. Oxford University on ComCov studies. Grants from EU Commission. Expert advisor to European Medicines Agency. Honoraria for GSK and Pfizer. Finnish Institute for Health and Welfare receives funding from Sanofi Pasteur. GlaxoSmithKline.
Prof Shabir Madhi	Univ of the Witwatersrand, Johannesburg, SA	Funding from Pfizer, Minervax, GlaxoSmithKline, Novavax. Bill & Melinda Gates Foundation. Member of International Vaccine Institute (IVI) Scientific Advisory Committee. BMGF Global Health Scientific Advisory Committee. Advisor to the Pfizer Group B streptococcal (GBS) vaccine program. Member of the Data and Safety Monitoring Board (DSMB) of GSK and Janssen. Chair of the DSMB of CAPRISA. Clinical-Regulatory Advisory Board of CureVac for Covid-19 vaccine. National Principal Investigator, AstraZeneca ChAdOx-nCoV19 vaccine. Wits Health Consortium funded by Novartis, GSK, Medimmune, Novavax. Mitsubishi. Merck (MSD), Novavax .
Prof Peter McIntyre	Dunedin School of Medicine, Univ of Otago, Dunedin, New Zealand	Member of the DSMB for the Novavax Covid-19 vaccine. Member of the New Zealand Scientific and TAG on COVID-19 vaccines. Deputy Director of Australia's National Centre for Immunisation Research and Surveillance of Vaccine-Preventable Diseases (NCIRS). investigator on Wellcome Trust grant.

# Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Anthony Scott	London School of Hygiene and Tropical Medicine. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya	Funding from Wellcome Trust, Bill and Melinda Gates Foundation, National Institute for Health Research (NIHR). Worked with WHO and GAVI on vaccines. Joint Committee on Vaccination and Immunisation (JCVI) Board member. Director of the NIHR Health Protection Research Unit in Immunisation. Advisor to UK Health Security Agency. World Bank International Vaccines Task Force.
Prof Kathleen M. Neuzil	Director, Univ of Maryland School of Medicine, Baltimore, USA	Funding from Pfizer and NIH. Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021). CDC Advisory Committee on Immunization. Serum Institute of India, Ltd. Co-chair of the NIH COVID Vaccine Prevention Network. Univ of Maryland funding from GSK, Merck, Nosocomial Vaccine Corporation, ICON Clinical Research. Previous employment: PATH. Studied at Johns Hopkins University School of Medicine. Member on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. Associate Editor of the journal Vaccine
Prof Kim Mulholland	Professor of Child Health and Vaccinology, London School of Hygiene and Tropical Medicine. Murdoch Children's Research Institute (MCRI), Melbourne, Australia	Safety Monitoring Committee from the Novavax Covid-19 Vaccine. Novavax Maternal RSV immunization project. PCV13 vaccination project on adult pneumonia in Mongolia funded by Pfizer. Principal Investigator in pneumococcal vaccine trials 1 and 2 funded by the Bill and Melinda Gates Foundation. Member of Gates Foundation DeCoDe Committee to review CHAMPS. Receives funding from GAVI.
Prof Noni MacDonald	Paediatrics, Dalhousie University, Halifax, Canada	Funding from Bill and Melinda Gates Foundation, WHO (Consultancy). Academic Committee Member of Leger, Canada. Board member of International Vaccine Institute. Member of the SAGE Working Group on Vaccine Hesitancy

# Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Rakesh Aggarwal	Director, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India	MSc from London School of Hygiene and Tropical Medicine
Dr Jaleela Jawad	Consultant, Ministry of Health Manama, Bahrain	CDC USA
Dr Sonali Kochhar	Assoc Prof, Univ of Washington, Seattle, USA	Funding from Bill & Melinda Gates Foundation, Wellcome Trust.
Prof Punnee Pitisuttithum	Mahidol University, Bangkok, Thailand	Safety Monitoring Committee for the U.S. Military HIV Research Program. Principal investigator Safety of Tri Fluvac influenza vaccine and MSD-funded 9vHPV vaccine.
Dr Folake Olayinka	Immunization Team Leader, USAID (Public Health Institute STAR Fellow). Washington, USA	Advisor to the WHO-AFRO Regional Immunization Technical Advisory Group.
Dr Ezzeddine Mohsni	Programme Essaha Aziza, European Union Tunis, Tunisia	Funding from Bill and Melinda Gates Foundation, Gavi and WHO.
Dr Ilesh V. Jani	Director General, National Institute of Health, Marracuene, Mozambique	Funding from CEPI and Bill and Melinda Gates Foundation, Janssen Vaccines & Prevention B.V., US National Institutes of Health (NIH), the HIV Vaccine Trial Network (HVTN). Grant/research support from WHO
Prof Andrew Pollard (former member)	Director of the Oxford Vaccine Group	Chief investigator for the Oxford-AstraZeneca COVID-19 vaccine clinical trials. Chair, Joint Committee on Vaccination and Immunisation (JCVI), Chair Scientific Advisory Group on Vaccines at the European Medicines Agency, National Institute for Health and Care Excellence (NICE, UK). Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, Advisor to the European Medicine Agency (EMA). Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK. Funding from Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),

# International Health Regulations Committee (IHR)

---

## Conflicts of Interest

# International Health Regulations (IHR) Committee



Prof Arnold Monto,  
University of Michigan

- \* Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

- \* Consultant for GSK, Novartis, Roche, Baxter and Sanofi

- \* His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Neil M. Ferguson  
Imperial College, London

- \* Scientific Advisory Group for Emergencies (SAGE)(UK)
- \* Head of International Health Regulations (IHR) (2005) Emergency Steering Committee

- \* Consultant for Roche, Novartis, Baxter and GSK Biologicals

- \* Funding from Sanofi, Janssen, Thermo-Fischer Scientific

- \* Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

- \* Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza

- \* Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon  
Deputy Director Public Health England

- \* Member UK Scientific Advisory Group for Emergencies (SAGE)

- \* Deputy Director Public Health England

- \* Member of International Health Regulations (IHR) (2005) Steering Committee

- \* Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London

- \* UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.

- \* Publications funding: Bill and Melinda Gates Foundation Wellcome Trust

- \* Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization




Masato Tashiro

- \* Director, WHO Collaborating Centre for Reference and Research on Influenza

- \* WHO Essential Reference Laboratory of GISRS

# Prof Neil Ferguson: Covid Modeller and Major Conflicts of Interest





World Health Organization

# Big Pharma Conflicts of Interests

## WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics 2004

**Prof. Karl Nicholson**, Member of The European Scientific Working Group on Influenza (ESWI), **Prof. Frederick Hayden**, University of Virginia, **Dr. Arnold Monto**, University of Michigan

Prof Nicholson is on the **Roche** pharmaceutical Company Payroll. He conducted a randomised controlled trial on oseltamivir (Tamiflu) supported by **Roche** and also received travel sponsorship and honorariums from **GlaxoSmithKline and Roche** for consultancy work and speaking at international respiratory and infectious diseases symposiums

Prof Hayden paid by **Roche** for lectures and consultancy work for the company at the time the guidance was produced and published, also received payments from **GlaxoSmithKline** for consultancy and lecturing until 2002. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE) and Board of Wellcome Trust

Prof Monto received honorariums, consultancy fees, and research support from **GSK, Novartis, Roche, Baxter and Sanofi, MedImmune**, consultancy fees and research (GlaxoSmithKline, \$3000 speakers fees in 2009) and also research funding from ViroPharma.



Prof. Karl Nicholson



Prof. Fred Hayden



Dr. Arnold Monto



World Health Organization

&

**ESWI**

...scientists fighting influenza

Sponsors



**Benevolent  
Philanthropist**



**Corporate  
Hegemon**

**OR**



# Wellcome Trust Ltd invested in Corporate Elite











Company	Investment Sector	Share Value (\$ millions)
Microsoft	IT, Software Development	\$942
Alphabet (Google)	Multinational Technology	\$801
Facebook (Metaverse)	Social Media Platform	\$509
Amazon	e-Commerce	\$592
Berkshire Hathaway	Asset Management	\$549
Bank Of America Corp	Corporate Banking Services	\$445
JP Morgan Chase & Co	Investment bank and Financial Services	\$391
Apple Inc	Computer electronics, software and online	\$747
Mastercard Inc	Multinational Financial Services	\$69
VISA INC	Multinational Financial Services	\$520
Door Dash Inc	Real Estate	\$744
Accenture	Information technology services and consulting	\$456
Cisco Systems	Cybersecurity, Cloud and Network	\$411
Adobe	Marketing and Document Management	\$357
Nike	Footwear, apparel, clothing, equipment	\$350
Krispy Kreme Inc	International doughnut and coffee chain	\$30
Pepsico	Transnational Beverage company	\$365
Royal Dutch Shell	Multinational Oil & Gas Corporation	\$301
BP	Multinational Oil & Gas Corporation	\$191

# Wellcome Trust Ltd invested in Big Pharma

Company	Products	Share Value (\$ millions)
Johnson & Johnson	Pharmaceuticals, Covid Vaccines	\$407
Novartis	Covid Vaccines	\$371
Roche	Covid Pharmaceuticals, Vaccines	\$439
Abbott Laboratories	Drugs, Covid Diagnostic Kits (PCR)	\$246 (2 million shares)
Sequoia Pharmaceuticals	Vaccines	NA
Merck	Covid Pharmaceuticals, Vaccines	NA
Biogen	Neurotherapeutics	NA
Teva	Generic Covid Drugs	NA
Abbvie	Antivirals	NA
Syncona	Therapeutics	NA

NA – Not Available

# Wellcome Trust invested in Covid-19 Industry

Shareholders	Covid Products	Value of Shares
	Ad26.COVS.S COVID-19 DNA Vaccine	£266m
	Regeneron RegN-Cov 2 Roche-Atea's Covid-19 pill ePlex SARS-CoV-2 Test Elecsys IL-6 test Elecsys Anti-SARS-CoV-2 antibody test cobas 5800 SARS-CoV-2 Qualitative Test	£326m
	 ensovibep dexamethasone	£275m
	BinaxNOW RAPID COVID ANTIGEN TEST Panbio™ COVID-19 Ag Rapid Test Device	£182m
	molnupiravir	NA
	VIR-7832 Covid-19 monoclonal antibody	NA
	NA	NA
	NA	NA
	NA	£273m

# Wellcome Trust invested in Covid-19 Industry

BERKSHIRE HATHAWAY INC.



**NOVARTIS**



the RNA people®  
Dexamethasone  
ensovibep



**Johnson & Johnson**

Ad26.COVS.2 COVID-19 Vaccine




**THE JENNER INSTITUTE**  
DEVELOPING INNOVATIVE VACCINES

ChAdOx1 nCov-19 Covid Vaccine



**MERCK**

molnupiravir



**abbvie**



**Biogen**


VIR-7832 Covid-19 monoclonal antibody



**teva**




**wellcome**



**Roche**

Regeneron RegN-Cov 2  
Roche-Atea's Covid-19 pill  
ePlex SARS-CoV-2 test  
Elecsys IL-6 test  
Elecsys Anti-SARS-CoV-2 antibody test  
cobas 5800 SARS-CoV-2 Qualitative test



**Abbott**  
A Promise for Life

BinaxNOW RAPID COVID ANTIGEN TEST  
Panbio™ COVID-19 Ag Rapid Test Device



**SIEMENS**



**MOLOGIC**  
BIG IN TINY SCIENCE



Rapid Point-of-Care Diagnostic Kit

  – Shareholder value  
 NA – Not Available

£275m

£266m

£15m

NA

NA

NA

NA

£182m

£326m

£1m

£273m

# Wellcome Trust invested in Covid-19 Industry

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST ownership in BRK.A / Berkshire Hathaway, Inc.

Security BRK.A / Berkshire Hathaway, Inc.

Institution WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST

Latest Disclosed Ownership 1,038 shares

Latest Disclosed Value \$ 549,020,000

Fintel®

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST ownership in BRK.A / Berkshire Hathaway, Inc.

2022-04-27 - WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST has filed a 13F-HR form disclosing ownership of 1,038 shares of Berkshire Hathaway, Inc. (US:BRK.A) with total holdings valued at \$549,020,000 USD as of 2022-03-31. WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST had filed a previous 13F-HR on 2022-02-01 disclosing 1,038 shares of Berkshire Hathaway, Inc. at a value of \$467,787,000 USD. This represents a change in shares of 0.00 percent and a change in value of 17.37 percent during the quarter.


Berkshire Share Holdings	Total Investment Value
Merck & Co.	\$ 1,415,927,482
Bristol-Myers Squibb Co.	\$ 2,080,710,820
Pfizer Inc	\$136 million
Johnson & Johnson (JNJ)	\$ 55,921,016
Teva Pharmaceutical Industries Ltd	\$ 471,538,031
Mastercard Inc (MA)	\$ 1,678,004,306
Vanguard 500 Index Fund ETF	\$ 16,403,210
Bank of America Corp	\$ 43,792,925,054



BERKSHIRE  
HATHAWAY

Fig. Warren Buffet, CEO Berkshire Hathaway Inc.

# Wellcome Trust: Global Elite Co-Conspirator in Covid-19 Pandemic Genocide and Conflicts on Interest



# Wellcome Trust invested in Covid-19 Industry

**The  
Guardian**  
For **200** years

11 Jan 2022

## Wellcome Trust to spend £16bn on research with focus on Covid vaccines

**Britain's biggest charity unveils spending plan over next decade after record return on investments**

# Wellcome Trust: Global Elite Co-Conspirator in Covid-19 Pandemic Genocide and Conflicts on Interest

## Wellcome Trust - Imperial College Centre for Global Health Research



Michael Levin



0 Collaborator(s)



Funding source

Wellcome Trust (WT)

FOLLOW

+ PROJECT

+ POST

+ EVENT

Info

People

Posts

Our vision is to contribute to understanding, preventing, and treating the major health problems of low- and middle-income countries (LMICs), through partnerships with academic institutions in Africa, Asia, and Latin America. We will integrate Imperial College London (ICL)'s expertise in Science, Engineering, Medicine, Public Health and Policy to study the health problems of global importance and build local research excellence. Collaborating teams will be supported to address major health problems of partner LMIC countries. Our Focus will be: 1. Mechanisms and population dynamics of tuberculosis (TB), HIV, HIV-TB, malaria, and neglected tropical diseases (NTDs). 2. Vaccine prevention and treatment of major childhood infections. 3. Non-communicable diseases (NCD's) including trends, risks and management of cardiometabolic conditions, chronic respiratory diseases, and selected cancers. 4. Integration of infection-NCD mechanisms and prevention including the role of infections and parasitic diseases on cancers and cardiovascular diseases; smoking and diabetes on TB susceptibility and progression; and the NCD

START DATE

2013-10-07

END DATE

2018-10-06

CANCER TYPES

Melanoma of skin

All cancers but non-melanoma skin cancer

PROJECT TYPES

Cancer Treatment

Capacity Building



# Wellcome Trust Ltd invested in Corporate Elite



## Williams Burns

CEO of Roche Holdings, is one of the Board of Governors of Wellcome Trust



## Elhadj As Sy

Co-chair of the WHO/World Bank Global Pandemic Preparedness Monitoring Board, and Board of Governors of Wellcome Trust



HOME > ASIA

# Shanghai installs metal barriers and fences around people's homes to stop them from going out, in its latest brutal measure to battle Covid

Waiyee Yip 2 hours ago



# Wellcome Trust invested in Covid-19 Industry

## Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19



SEATTLE, March 10, 2020 – The Bill & Melinda Gates Foundation, WELLCOME, and Mastercard today committed up to \$125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.



BILL &  
MELINDA  
GATES  
*foundation*



**Mastercard**

# Wellcome Trust Investment Portfolio 2020

We manage a significant portion directly...



Our direct shareholdings are a diverse subset of the world's best companies. We hold these stocks with a long term view, leading to very low turnover.

# Wellcome Trust Investment Portfolio 2021

Wellcome Bond Investor Update Presentation (11th January 2022)



# Wellcome Trust Ltd invested in Corporate Elite

thebmj

covid-19

Research ▾

Education ▾

News & Views ▾

Campaigns ▾

Jobs

**Feature** » Investigation

**Covid-19, trust, and Wellcome: how charity's pharma investments overlap with its research efforts**

*BMJ* 2021 ; 372 doi: <https://doi.org/10.1136/bmj.n556> (Published 03 March 2021)

**The major funder of health research stands to gain financially from the pandemic, raising questions about transparency and accountability**

The BMJ finds, Wellcome itself holds investments in companies producing these same treatments. Financial disclosures from late 2020 show that Wellcome has a £275m (€318m; \$389m) stake in Novartis, which manufactures dexamethasone and is investigating additional therapeutics. And Roche, in which Wellcome holds a £252m stake, is helping to manufacture monoclonal antibodies with Regeneron. Both Roche and Novartis report having had conversations with WHO's ACT Accelerator about their therapeutic drugs

**Wellcome also influences the pandemic response through Farrar's position on the Scientific Advisory Group for Emergencies advising the UK government on covid-19, as well as his board seat on the Coalition for Epidemic Preparedness Innovations, a leading public-private partnership in the pandemic that has pledged more than \$1bn to covid-19 vaccine development**

**Wellcome reports gains of £3.3bn from all investments in 2020, three times more money than the trust gave away in charity**

**Two investment companies on the calls with Farrar—Sequoia and Blackstone—have paid out dividends to Wellcome in recent years**

# Wellcome Trust invested in Covid-19 Industry

## Wellcome has been at the Centre of the Global Pandemic Response

**We are dedicated to improving health** and we fund health-related research across the world

**Wellcome has played a key role in the global pandemic research response**

**We are active participants in CEPI, (which Wellcome helped to found), Gavi and the WHO.**

### Some examples of Wellcome's role in the global pandemic response:



The Covid-19 Therapeutics Accelerator (CTA) started in March 2020 with support from Wellcome, Mastercard and the Bill & Melinda Gates Foundation. In its first year, the CTA committed over \$90m to clinical trials, therapeutic candidate discovery research, platforms to collect real-world evidence and data, and extra manufacturing capacity



Wellcome is part of the **Access to Covid-19 Tools (ACT) Accelerator**, which was set up by the WHO to ensure **global equitable access to the best vaccines and treatments**




The **RECOVERY trial**, which Wellcome supports through core funding and grants, has been at the **forefront of testing potential treatments** and identifying those that are effective at reducing the severity of illness people experience.



The Wellcome Sanger Institute is providing **large-scale, high-throughput genome sequencing and analysis of the Covid virus**, alongside many other avenues of research to support the pandemic response in the UK and internationally. This has not stopped other programmes of research from continuing, including work on human and animal genetics.


# A Globally Diversified Portfolio...

By Asset Class



- The portfolio is diversified both across and within asset classes
- The portfolio's exposure to public equities as a proportion to total assets reduced through FY 2020/21 due to the strong performance of our private investments.
- Our exposure to private equity increased due to exceptional performance. The largest part of our private equity exposure is venture capital, which continues to benefit from rapid technological innovation and a structural shift to the digital economy.

By Sector (of Public and Private Equity Exposure)



- There has been little change to our public and private equity sector positioning over FY 2020/21. Exposure to information technology sector increased slightly from 25% to 28%, while consumer discretionary (which includes e-commerce) exposure remains at 19%.
- While healthcare and consumer staples have performed relatively poorly, there are some pockets of value which we have added to. We have increased our healthcare exposure slightly to 13%.



# Wellcome Trust invested in Vaccine Industry



The image shows a screenshot of the Financial Times website. At the top, the 'FINANCIAL TIMES' logo is centered, with a search icon to its left and 'Subscribe' and 'Sign In' buttons to its right. Below the logo is a navigation bar with links for HOME, WORLD, US, COMPANIES, TECH, MARKETS, CLIMATE, OPINION, WORK & CAREERS, LIFE & ARTS, and HOW TO SPEND IT. The main content area features a large headline: 'Become an FT subscriber to read: Merck and Wellcome Trust in vaccine alliance'. To the right of this text is an image of a laptop, tablet, and smartphone displaying the Financial Times website. Below the headline, there is a sub-headline 'Make informed decisions with the FT' and a paragraph: 'Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.'

FINANCIAL TIMES

Subscribe Sign In

HOME WORLD US COMPANIES TECH MARKETS CLIMATE OPINION WORK & CAREERS LIFE & ARTS HOW TO SPEND IT

Become an FT subscriber to read:

## Merck and Wellcome Trust in vaccine alliance

**Make informed decisions with the FT**

Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.



# Wellcome Trust invested in Vaccine Industry



Filling the need for trusted information on national health issues

DONATE



TRENDING

[COVID-19 Vaccine Monitor Dashboard](#)

[Mental Health](#)

[Public Health Emergency](#)

[Home](#) // [Global Health Policy](#) // [KFF Daily Global Health Policy Report](#) // [January 25, 2011](#)

## Merck, Wellcome Trust Back Project To Develop Improved Rotavirus Vaccine For Developing Countries

Jan 25, 2011



"A joint venture between U.S. drugmaker Merck and Britain's Wellcome Trust charity said on Monday it is working on an oral rotavirus vaccine designed to be cheaper and easier to use than current shots," [Reuters](#) reports. "Hilleman Laboratories, an India-based joint venture set up on a not-for-profit basis in 2009, said the vaccine will aim to protect against diarrhea-causing rotavirus infections and will be based on thin strips or granules that dissolve in the mouth and can be easily transported, stored and administered."

SEARCH NEWS SUMMARIES FOR:

Enter Keyword



RECENT REPORTS

- › [December 17, 2020](#)
- › [December 16, 2020](#)
- › [December 15, 2020](#)
- › [December 14, 2020](#)
- › [December 11, 2020](#)

# Wellcome Trust invested in Vaccine Industry



---

**Julie Louise Gerberding, M.D., M.P.H.**

---

**Executive Vice-President and Chief Patient Officer,  
Strategic Communications, Global Public Policy and  
Population Health, MSD**

## Previous Positions

**President of Vaccines, Merck (2010)**

**Director of the U.S. CDC (through SARS)**

**MSD Wellcome Trust Hilleman Laboratories, Board Member)**



# Wellcome Trust invested in Vaccine Industry



## **Wellcome Trust to launch £200 million investment business for healthcare and life sciences**

The Board of Governors of the Wellcome Trust has approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors.

# Wellcome Trust invested in Vaccine Industry

March 8, 2019 10:33 AM EST | Discovery


[↻](#) [in](#) [🐦](#)

**ENDPOINTS**NEWS

## Merck gives King's College London, Wellcome Trust up to \$340M in deal to develop non-opioid painkillers



**Natalie Grover**  
Reporter



**MERCK**

**KING'S**  
*College*  
**LONDON**

**W**  
**wellcome**

# Wellcome Trust invested in Vaccine Industry

## Wellcome, Merck JV to make anti-diarrhoea vaccine for babies

ET Bureau • Last Updated: Jan 25, 2011, 06:41 AM IST

SHARE FONT SIZE SAVE PRINT COMMENT

### Synopsis

An Indian healthcare JV between Merck & Co and Wellcome Trust plans to develop heat stable oral rotavirus vaccine to prevent diarrhoea in babies in developing countries.

NEW DELHI: An Indian healthcare joint venture between drugmaker Merck & Co and UK-based charitable entity [Wellcome Trust](#) plans to develop heat stable oral rotavirus vaccine to prevent diarrhoea in babies in developing

# Wellcome Trust secret offshore investments



NEWS

CAREERS

COMMENTARY

JOURNALS ▾

Science



LOG IN

BECOME A MEMBER

[News Home](#)

[All News](#)

[ScienceInsider](#)

[News Features](#)

GET OUR E-ALERTS

[HOME](#) > [NEWS](#) > [SCIENCEINSIDER](#) > PRIVATE RESEARCH FUNDERS COURT CONTROVERSY WITH BILLIONS IN SECRETIVE INVESTMENTS

SCIENCEINSIDER | FUNDING

## Private research funders court controversy with billions in secretive investments

Critics say offshore investing by high-minded foundations shores up a nefarious system

6 DEC 2018 • BY [CHARLES PILLER](#)

# Wellcome Trust secret offshore investments

European Scientist



Join our newsletter

EN

Energy | Environment | Agriculture | Big Data | Public Health | Research | Features |

Home » Environment » Major research funders are stowing billions in offshore tax havens

- Environment -

## Major research funders are stowing billions in offshore tax havens

By Siobhán Dunphy - 06.12.2018



**Wellcome Trust is invested in 57 offshore tax haven funds**



# Wellcome Trust secret offshore investments

**TheScientist**  
EXPLORING LIFE, INSPIRING INNOVATION



Home / News & Opinion

## Research Funders Make Secretive Overseas Investments: Report

An investigation by *Science* reveals that charities' investments support activities opposed to their own missions, such as human health and environmental protection.

Ashley P. Taylor

Dec 6, 2018


PDF VERSION

**M**any big-name research funders place millions of dollars in offshore investments, which in turn may drive activities that run contrary to the causes the charities promote, according to an investigative report published today (December 6) in *Science*.

ABOVE: The Cayman Islands sometimes serve as a tax haven.  
© ISTOCK.COM, UNDEFINED

The investigation covered the investments of seven of the world's largest science funders. Of those, six charities—the Wellcome Trust, the Howard Hughes Medical Institute, the Robert Wood Johnson Foundation, the David and Lucile Packard Foundation, the Gordon and Betty Moore Foundation, and the William and Flora Hewlett Foundation—were found to have offshore investments that, combined, totaled at least \$5 billion in recent years. The one charity that was not found to invest offshore is the Bill &

# Wellcome Trust secret offshore investments

[NEWS](#)[CAREERS](#)[COMMENTARY](#)[JOURNALS](#) 

Science

Foundation	Endowment assets*	Known offshore investments
Bill & Melinda Gates Foundation	\$51.8 billion	None
Wellcome Trust	\$29.3 billion	\$926 million
Howard Hughes Medical Institute	\$20.4 billion	\$891 million
Robert Wood Johnson Foundation	\$10.8 billion	\$3+ billion
William and Flora Hewlett Foundation	\$9.9 billion	\$168 million
David and Lucille Packard Foundation	\$7.9 billion	\$140 million
Gordon and Betty Moore Foundation	\$6.9 billion	\$40 million

PARADISE PAPERS; FOUNDATIONS' MOST RECENT TAX RETURNS AND AUDITED FINANCIAL STATEMENTS

**Foundations that invest in tax havens need to know that ... they are alongside criminals, tax evaders, and kleptocrats.**